Antisense News and Research

RSS

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.

Transient receptor potential channel A1 causes calcitonin gene-related peptide release in neurons

Transient receptor potential channel A1 is one of the important transducers of noxious stimuli in the primary afferents, which may contribute to generation of neurogenic inflammation and hyperalgesia.

26 Dec 2013

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.

23 Dec 2013

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

13 Dec 2013

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Cyclin D1, a protein that helps push a replicating cell through the cell cycle also mediates the processing and generation of mature microRNA, according to new research publishing November 29 in Nature Communications. The research suggests that a protein strongly implicated in human cancer also governs the non-protein-coding genome. The non-coding genome, previously referred to as junk DNA, makes up most of the human genome, and unlike the coding genome, varies greatly between species.

29 Nov 2013

Isis Pharmaceuticals commences Phase 1 study of ISIS-GSK3Rx for treatment of common viral infection

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-GSK3Rx and earned a $3 million milestone payment from GlaxoSmithKline.

27 Nov 2013

Designation of ISIS-GSK4Rx as a development candidate triggers milestone payment to Isis

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.

15 Nov 2013

Study uncovers novel mechanism that helps govern regulated gene expression

A study led by researchers at the University of California, San Diego School of Medicine shines a new light on molecular tools our cells use to govern regulated gene expression. The study was published on line in advance of print November 10 in the journal Nature Structural and Molecular Biology.

13 Nov 2013

Researchers identify novel therapeutic approach for most frequent genetic cause of ALS

A team of scientists led by researchers from the University of California, San Diego School of Medicine and Ludwig Institute for Cancer Research have identified a novel therapeutic approach for the most frequent genetic cause of ALS, a disorder of the regions of the brain and spinal cord that control voluntary muscle movement, and frontal temporal degeneration, the second most frequent dementia.

10 Nov 2013

Scientists identify new toxic entity associated with dementia and motor neuron disease

A new toxic entity associated with genetically inherited forms of dementia and motor neuron disease has been identified by scientists at the UCL Institute of Neurology. The toxin is the result of a genetic mutation that leads to the production of RNA molecules which could be responsible for the diseases. The findings are published in the journal Acta Neuropathologica.

31 Oct 2013

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Inc. today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012. Non-GAAP diluted EPS for the third quarter of 2013 were $2.35, an increase of 23% over the third quarter of 2012.

28 Oct 2013

GSK Adds Another Program To Isis Antisense Collab

...

7 Oct 2013

ISIS conducts phase 2 study of ISIS-SMNRx in infants with type I spinal muscular atrophy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it dosed the first infant in the 12 mg dose group in the Phase 2 study evaluating ISIS-SMNRx in infants with Type I spinal muscular atrophy (SMA).

4 Oct 2013

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Isis Pharmaceuticals, Inc. announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy, show that most SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests up to 14 months after a single injection of the drug.

19 Sep 2013

Researchers develop TSUNAMI method to create animal model of adult-onset version of SMA

A research team at Cold Spring Harbor Laboratory has used a recently developed technology they call TSUNAMI to create the first animal model of the adult-onset version of spinal muscular atrophy, a devastating motor-neuron illness.

10 Sep 2013

Biogen Idec And Isis Ink Fourth Deal In Two Years

...

9 Sep 2013

Novel machine learning-based approach used to predict hepatotoxic potential of DNA drug

New classes of therapeutic antisense oligonucleotides can have toxic effects on the liver. A novel machine learning-based approach used to predict the hepatotoxic potential of an antisense drug based on its chemical sequence is presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

28 Aug 2013

ASO may correct striatal transcriptional abnormalities and improve behavioral problems in HD mice

Findings from postmortem studies of the brains of Huntington's Disease (HD) patients suggest that transcriptional dysregulation may be an early step in the pathogenesis of HD before symptoms appear. Other studies report transcriptional alterations in the brains of some mouse models of HD.

27 Aug 2013

Shire Renews Rare Genetic Disease Collab With Santaris

...

23 Aug 2013

Shire Renews Rare Genetic Disease Collab With Santaris

...

23 Aug 2013

Shire extends existing partnership with Santaris Pharma in rare genetic disease space

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that its long term partner, Shire has extended the existing partnership in the rare genetic disease space.

23 Aug 2013

Antisense News and Research

Transient receptor potential channel A1 causes calcitonin gene-related peptide release in neurons

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Study: Antisense drugs show activity in wide range of tissues and organs

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Isis Pharmaceuticals commences Phase 1 study of ISIS-GSK3Rx for treatment of common viral infection

Designation of ISIS-GSK4Rx as a development candidate triggers milestone payment to Isis

Study uncovers novel mechanism that helps govern regulated gene expression

Researchers identify novel therapeutic approach for most frequent genetic cause of ALS

Scientists identify new toxic entity associated with dementia and motor neuron disease

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

GSK Adds Another Program To Isis Antisense Collab

ISIS conducts phase 2 study of ISIS-SMNRx in infants with type I spinal muscular atrophy

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Researchers develop TSUNAMI method to create animal model of adult-onset version of SMA

Biogen Idec And Isis Ink Fourth Deal In Two Years

Novel machine learning-based approach used to predict hepatotoxic potential of DNA drug

ASO may correct striatal transcriptional abnormalities and improve behavioral problems in HD mice

Shire Renews Rare Genetic Disease Collab With Santaris

Shire Renews Rare Genetic Disease Collab With Santaris

Shire extends existing partnership with Santaris Pharma in rare genetic disease space

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News